Federated Investors Inc. PA Has $312,000 Position in Cempra, Inc. (CEMP)
Federated Investors Inc. PA boosted its holdings in Cempra, Inc. (NASDAQ:CEMP) by 251.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,771 shares of the biotechnology company’s stock after purchasing an additional 48,485 shares during the quarter. Federated Investors Inc. PA owned approximately 0.13% of Cempra worth $312,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in CEMP. Asset Management One Co. Ltd. acquired a new position in Cempra in the first quarter valued at $106,000. Janney Montgomery Scott LLC increased its stake in Cempra by 35.6% in the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 6,800 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new position in Cempra in the first quarter valued at $140,000. LMR Partners LLP acquired a new position in Cempra in the second quarter valued at $149,000. Finally, State of Wisconsin Investment Board acquired a new position in Cempra in the second quarter valued at $166,000. Hedge funds and other institutional investors own 49.75% of the company’s stock.
Shares of Cempra, Inc. (NASDAQ CEMP) opened at 3.15 on Friday. The firm’s market capitalization is $165.40 million. The firm’s 50-day moving average price is $3.18 and its 200 day moving average price is $3.79. Cempra, Inc. has a 52 week low of $2.55 and a 52 week high of $26.95.
Cempra (NASDAQ:CEMP) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The business’s revenue was down 74.9% compared to the same quarter last year. During the same period last year, the company earned ($0.51) earnings per share. On average, analysts anticipate that Cempra, Inc. will post ($1.01) EPS for the current year.
Several equities analysts recently commented on the company. ValuEngine lowered Cempra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Roth Capital lowered Cempra from a “buy” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $4.00 in a research note on Thursday, August 10th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 target price on shares of Cempra in a research note on Thursday, August 10th. Zacks Investment Research lowered Cempra from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $3.00 target price on shares of Cempra in a research note on Thursday, September 14th. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $10.00.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.